NO20052479L - Delayed release tramadol formulations and 24 hour efficacy - Google Patents

Delayed release tramadol formulations and 24 hour efficacy

Info

Publication number
NO20052479L
NO20052479L NO20052479A NO20052479A NO20052479L NO 20052479 L NO20052479 L NO 20052479L NO 20052479 A NO20052479 A NO 20052479A NO 20052479 A NO20052479 A NO 20052479A NO 20052479 L NO20052479 L NO 20052479L
Authority
NO
Norway
Prior art keywords
delayed release
release tramadol
tramadol formulations
hour efficacy
efficacy
Prior art date
Application number
NO20052479A
Other languages
Norwegian (no)
Other versions
NO20052479D0 (en
Inventor
Vincent Lenaerts
Patricia Laure Ouadji-Njiki
Jonathan Bacon
Rachid Quzerourou
Sonia Gervais
Miloud Rahmouni
Damon Smith
Original Assignee
Labopharm Europe Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32179487&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20052479(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Labopharm Europe Ltd filed Critical Labopharm Europe Ltd
Publication of NO20052479D0 publication Critical patent/NO20052479D0/en
Publication of NO20052479L publication Critical patent/NO20052479L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Det er beskrevet en opprettholdt frigjøringsttamadolformulering for oral administtering som etter initiell administtering av en dose tilveiebringer en analgetisk sammensetning irmen to timer, hvor den analgetiske virkningen fortsetter i minst 24 timer etter administtering.There is disclosed a sustained release tamadol formulation for oral administration which after initial administration of a dose provides an analgesic composition for at least two hours, the analgesic effect continuing for at least 24 hours after administration.

NO20052479A 2002-10-25 2005-05-23 Delayed release tramadol formulations and 24 hour efficacy NO20052479L (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28102602A 2002-10-25 2002-10-25
US51037803P 2003-10-10 2003-10-10
PCT/CA2003/001638 WO2004037222A2 (en) 2002-10-25 2003-10-27 Sustained-release tramadol formulations with 24-hour efficacy

Publications (2)

Publication Number Publication Date
NO20052479D0 NO20052479D0 (en) 2005-05-23
NO20052479L true NO20052479L (en) 2005-05-23

Family

ID=32179487

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20052479A NO20052479L (en) 2002-10-25 2005-05-23 Delayed release tramadol formulations and 24 hour efficacy

Country Status (11)

Country Link
JP (1) JP2006507277A (en)
KR (1) KR20050083816A (en)
AR (1) AR045972A1 (en)
AU (1) AU2003275855B2 (en)
CA (1) CA2503155A1 (en)
IL (1) IL168114A (en)
NO (1) NO20052479L (en)
PT (1) PT1594460E (en)
RU (1) RU2328275C2 (en)
UA (1) UA84277C2 (en)
WO (1) WO2004037222A2 (en)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
TWI319713B (en) 2002-10-25 2010-01-21 Sustained-release tramadol formulations with 24-hour efficacy
US8487002B2 (en) 2002-10-25 2013-07-16 Paladin Labs Inc. Controlled-release compositions
EP1905435A3 (en) * 2003-03-11 2008-05-14 Euro-Celtique S.A. Titration dosing regimen for controlled release tramadol
US7413749B2 (en) * 2003-03-11 2008-08-19 Purdue Pharma L.P. Titration dosing regimen for controlled release tramadol
DE10361596A1 (en) 2003-12-24 2005-09-29 Grünenthal GmbH Process for producing an anti-abuse dosage form
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE10336400A1 (en) 2003-08-06 2005-03-24 Grünenthal GmbH Anti-abuse dosage form
DE102005005446A1 (en) 2005-02-04 2006-08-10 Grünenthal GmbH Break-resistant dosage forms with sustained release
ES2485867T3 (en) * 2004-05-14 2014-08-14 Janssen Pharmaceutica Nv Opioid Carboxamide Compounds
DE102004032049A1 (en) 2004-07-01 2006-01-19 Grünenthal GmbH Anti-abuse, oral dosage form
DE102005005449A1 (en) 2005-02-04 2006-08-10 Grünenthal GmbH Process for producing an anti-abuse dosage form
EA014739B1 (en) * 2005-09-09 2011-02-28 Лабофарм Инк. TRAZODON COMPOSITION FOR INTRODUCTION ONCE A DAY
RU2008113439A (en) 2005-09-09 2009-10-20 Лабофарм Инк. (CA) COMPOSITIONS WITH SLOW DELIVERY OF A MEDICINAL PRODUCT
HUE029173T2 (en) * 2006-04-26 2017-02-28 Alphapharm Pty Ltd Controlled release formulations comprising uncoated discrete unit(s) and an extended release matrix
CA2713128C (en) 2008-01-25 2016-04-05 Gruenenthal Gmbh Pharmaceutical dosage form
BRPI0912014A2 (en) 2008-05-09 2019-03-06 Grünenthal GmbH A process for preparing an intermediate powder formulation and a final solid dosage form using a spray freeze step
BRPI0912126A2 (en) 2008-05-27 2015-11-03 Univ Melbourne method of treating mammals with eustachian tube dysfunction
CN107028908A (en) * 2008-10-27 2017-08-11 阿尔扎公司 Extended release oral acetaminophen/tramadol dosage form
RU2015138422A (en) 2009-07-22 2018-12-25 Грюненталь Гмбх STABLE DURING OXIDATION, STRONG-BREAKED DOSAGE FORM
CN102573805A (en) 2009-07-22 2012-07-11 格吕伦塔尔有限公司 Hot-melt extruded controlled release dosage form
US9579285B2 (en) 2010-02-03 2017-02-28 Gruenenthal Gmbh Preparation of a powdery pharmaceutical composition by means of an extruder
NZ607392A (en) 2010-09-02 2015-03-27 Gruenenthal Chemie Tamper resistant dosage form comprising inorganic salt
BR112013005234A2 (en) 2010-09-02 2016-05-03 Gruenenthal Gmbh Tamper resistant dosage form comprising an anionic polymer.
PE20141638A1 (en) 2011-07-29 2014-11-22 Gruenenthal Chemie HANDLE PROOF TABLET PROVIDING IMMEDIATE DRUG RELEASE
RS56527B1 (en) 2011-07-29 2018-02-28 Gruenenthal Gmbh Tamper-resistant tablet providing immediate drug release
MX356421B (en) 2012-02-28 2018-05-29 Gruenenthal Gmbh Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer.
DK2838512T3 (en) 2012-04-18 2018-11-19 Gruenenthal Gmbh MANIPULATED AND DOSAGE DUMPED PHARMACEUTICAL DOSAGE FORM
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
AR096439A1 (en) 2013-05-29 2015-12-30 Gruenenthal Gmbh DOSAGE METHOD RESISTING TO INDEED USE CONTAINING ONE OR MORE PARTICLES
JP6445537B2 (en) 2013-05-29 2018-12-26 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング Tamper-resistant dosage forms containing one or more particles
US10624862B2 (en) 2013-07-12 2020-04-21 Grünenthal GmbH Tamper-resistant dosage form containing ethylene-vinyl acetate polymer
AU2014356581C1 (en) 2013-11-26 2020-05-28 Grunenthal Gmbh Preparation of a powdery pharmaceutical composition by means of cryo-milling
MX2016014738A (en) 2014-05-12 2017-03-06 Gruenenthal Gmbh Tamper resistant immediate release capsule formulation comprising tapentadol.
MX2016015417A (en) 2014-05-26 2017-02-22 Gruenenthal Gmbh Multiparticles safeguarded against ethanolic dose-dumping.
JP2018517676A (en) 2015-04-24 2018-07-05 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング Anti-modification formulation with immediate release and resistance to solvent extraction
AU2016319203A1 (en) 2015-09-10 2018-02-22 Grünenthal GmbH Protecting oral overdose with abuse deterrent immediate release formulations
JP7653218B2 (en) 2016-05-05 2025-03-28 アクエスティブ セラピューティクス インコーポレイテッド Enhanced Delivery Epinephrine Compositions
EP3452024A1 (en) * 2016-05-05 2019-03-13 Aquestive Therapeutics, Inc. Pharmaceutical compositions with enhanced permeation
US12465564B2 (en) 2021-10-25 2025-11-11 Aquestive Therapeutics, Inc. Oral and nasal compositions and methods of treatment

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ260408A (en) * 1993-05-10 1996-05-28 Euro Celtique Sa Controlled release preparation comprising tramadol
DE19530575A1 (en) * 1995-08-19 1997-02-20 Gruenenthal Gmbh Rapidly disintegrating drug form of tramadol or a tramadol salt
WO1999001111A1 (en) * 1997-07-02 1999-01-14 Euro-Celtique, S.A. Stabilized sustained release tramadol formulations
DE10015479A1 (en) * 2000-03-29 2001-10-11 Basf Ag Solid oral dosage forms with delayed release of active ingredient and high mechanical stability
US6607748B1 (en) * 2000-06-29 2003-08-19 Vincent Lenaerts Cross-linked high amylose starch for use in controlled-release pharmaceutical formulations and processes for its manufacture
DE10108122A1 (en) * 2001-02-21 2002-10-02 Gruenenthal Gmbh Medicines based on tramadol

Also Published As

Publication number Publication date
IL168114A (en) 2011-05-31
RU2005115855A (en) 2006-01-20
JP2006507277A (en) 2006-03-02
NO20052479D0 (en) 2005-05-23
CA2503155A1 (en) 2004-05-06
KR20050083816A (en) 2005-08-26
AR045972A1 (en) 2005-11-23
AU2003275855A1 (en) 2004-05-13
PT1594460E (en) 2008-06-27
UA84277C2 (en) 2008-10-10
RU2328275C2 (en) 2008-07-10
WO2004037222A3 (en) 2005-09-22
AU2003275855B2 (en) 2009-04-23
WO2004037222A2 (en) 2004-05-06

Similar Documents

Publication Publication Date Title
UA84277C2 (en) Sustained-release tramadol formulations with 24-hour efficacy
NO20050379L (en) Use of venlafaxine hydrochloride for the preparation of an encapsulated extended release mixture
NO20080827L (en) Solid dosage formulations of narcotic drugs that have improved buccal adsorption
IL165264A (en) Protein kinase inhibitors, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments for treating protein kinase-associated diseases
NO20080164L (en) N- (pyridin-2-yl) -sulfonamidderivater
CY1105120T1 (en) THE TREATMENT OF RESPIRATORY DISEASES
BR0306870A (en) Oral pharmaceutical composition and method for preparing the same
PL369108A1 (en) 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
UA84266C2 (en) Oral dosage form containing a pde 4 inhibitor as an active ingredient and polyvinylpyroolidon as excipient, processes for the preparation and use thereof
DK1487829T3 (en) Thiadizolylpiperazine derivatives useful for treating or preventing pain
NO20062513L (en) Compositions and dosage forms for enhanced absorption of metformin
NO20042161L (en) Inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1
EP2298416A3 (en) Sustained-release tramadol formulations with 24-hour clinical efficacy
NO20051389L (en) Stabilized pharmaceutical composition containing basic aids
NO20045486L (en) New compounds and their use
CY1111470T1 (en) NEW PHARMACEUTICAL COMPOSITIONS CONTAINING FLYVERSERIN POLYMORPH A
DE602005007339D1 (en) NEBIVOLOL AND ITS NON-PHARMACEUTICAL SALTS, METHOD OF MANUFACTURE AND PHARMACEUTICAL COMPOSITIONS OF NEBIVOLOL
DE60323765D1 (en) INHIBITORS OF 17-BETA-HYDROXYSTEROIDDEHYDROGENASE OF TYPE 3 FOR THE TREATMENT OF ANDROGEN-DEPENDENT DISEASES
DK1594460T3 (en) Extended release tramadol formulations and 24 hour efficacy
NO304113B1 (en) Crystalline thiagabine hydrochloride monohydrate, pharmaceutical composition comprising it, and use thereof for the manufacture of a medicament
WO2004071374A3 (en) Once a day orally administered pharmaceutical compositions
EA200800783A1 (en) TRAZODON COMPOSITION FOR INTRODUCTION ONCE A DAY
DK1228758T3 (en) Use of sulfodehydroabietic acid for the treatment of inflammatory bowel disease
MX2007006635A (en) Pharmaceutical formulation of carboxamide hiv integrase inhibitors containing a release rate controlling composition.
NO20050771L (en) Bicifadinformulering

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application